34 results about "Brain swelling" patented technology

The present invention is directed to therapeutic compounds, treatment methods, and kits affecting the NCCa-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system, and methods of using same. The NCCa-ATP channel is newly expressed in neural tissue following injury such as ischemia, and is regulated by the sulfonylurea receptor SUR1, being inhibited by sulfonylurea compounds, e.g., glibenclamide and tolbutamide, and opened by diazoxide. Antagonists of the NCCa-ATP channel, including SUR1 antagonists, are useful in the prevention, diminution, and treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury. Agonists of the NCCa-ATP channel may be are useful in the treatment neural tissue where damage or destruction of the tissue, such as a gliotic capsule, is desired.

The present invention is directed to a combination of therapeutic compounds and treatment methods and kits using the combination. In particular, one of the combination affects the NCCa-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system. Exemplary SUR1 and / or TRPM4 antagonists that inhibit the NCCa-ATP channel may be employed in the combination. The combination therapy also employs one or more of a non-selective cation channel blocker and / or an antagonist of VEFG, NOS, MMP, or thrombin. Exemplary indications for the combination therapy includes the prevention, diminution, and / or treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury, for example. In other embodiments, there are methods and compositions directed to antagonists of TRPM4, including at least for therapeutic treatment of traumatic brain injury, cerebral ischemia, central nervous system (CNS) damage, peripheral nervous system (PNS) damage, cerebral hypoxia, or edema, for example.

The invention relates to a medicament for treating arthralgia and myalgia. The medicament is prepare from the components in parts by weight as follows: 1000 parts of nux vomica, 100 parts of radix clematidis, 100 parts of caulis sinomenii, 100 parts of garden balsam stem, 100 parts of lycopodium clavatum, 100 parts of berba aristolochiae mollissimae, 100 parts of monkshood, 100 parts of radix aconiti agrestis, 100 parts of the root of red-rooted salvia, 100 parts of angelica sinensis, 100 parts of rheum officinale, 100 parts of dragon's blood, 100 parts of semen momordicae, 100 parts of eucommia ulmoides, 100 parts of cinnamon, 100 parts of radix angelicae pubescentis, 100 parts of notopterygium root, 100 parts of asarum, 100 parts of radix achyranthis bidentatae, 100 parts of homalomena occulta, 100 parts of anisetree bark, 100 parts of radices sileris, 100 parts of caper, 100 parts of monkshood, 100 parts of ligusticum wallichii, 100 parts of Chinese polyphaga, 100 parts of scorpio, 100 parts of centipede, 100 parts of frankincense, 100 parts of myrrh, 100 parts of leech, 60 parts of camphor, 60 parts of borneol, 20 parts of musk and 300 parts of zaocys dhumnade. The medicament provided by the invention can be used for treating cervical spondylosis, brain swelling cervical pain, scapulohumeral periarthritis, scapula back pain, pelvospondylitis, thoracic vertebra pain, elbow joint pain, pain in waist and lower extremities, lumbar disc herniation, cervical and lumbar spinal stenosis, osteoproliferation, ischiadic nerve pain, knee-joint dropsy, synovitis, knee pain and rheumatic arthritis.

The present disclosure provides dynamic cranial fixation devices and related methods for attaching a resected bone portion(s), or a bone flap, to the skull in such a manner that allows for brain swelling to occur with minimal constraint following a craniotomy or craniectomy. The present disclosure provides dynamic cranial fixation devices and related methods that provide outward movement of the bone flap as the brain swells underneath the bone flap to prevent or reduce a rise in the intracranial pressure. Once the brain swelling resolves, the dynamic cranial fixation devices and related methods of the present disclosure allow the bone flap to return to its original position (before resection) without further surgery, implantation or the like. Once the bone flap return to its original position (or substantially similar position), the bone flap may fuse with the neighboring bone(s), potentially with the assistance of one or more fusion aid.